Suppr超能文献

心脏手术后预防持续性疼痛的普瑞巴林和氯胺酮的长期围手术期应用。

Prolonged Perioperative Use of Pregabalin and Ketamine to Prevent Persistent Pain after Cardiac Surgery.

机构信息

From the Department of Perioperative Medicine, Barts Heart Centre, London, United Kingdom (S.A.) National Institutes of Health Research Biomedical Research Centre at Barts, London, United Kingdom (S.A., J.C.) Pain and Anaesthesia Research Centre, St. Bartholomew's Hospital, London, United Kingdom (S.A., J.R., C.S., R.L.).

出版信息

Anesthesiology. 2019 Jul;131(1):119-131. doi: 10.1097/ALN.0000000000002751.

Abstract

BACKGROUND

Persistent postsurgical pain is common and affects quality of life. The hypothesis was that use of pregabalin and ketamine would prevent persistent pain after cardiac surgery.

METHODS

This randomized, double-blind, placebo-controlled trial was undertaken at two cardiac surgery centers in the United Kingdom. Adults without chronic pain and undergoing any elective cardiac surgery patients via sternotomy were randomly assigned to receive either usual care, pregabalin (150 mg preoperatively and twice daily for 14 postoperative days) alone, or pregabalin in combination with a 48-h postoperative infusion of intravenous ketamine at 0.1 mg · kg · h. The primary endpoints were prevalence of clinically significant pain at 3 and 6 months after surgery, defined as a pain score on the numeric rating scale of 4 or higher (out of 10) after a functional assessment of three maximal coughs. The secondary outcomes included acute pain, opioid use, and safety measures, as well as long-term neuropathic pain, analgesic requirement, and quality of life.

RESULTS

In total, 150 patients were randomized, with 17 withdrawals from treatment and 2 losses to follow-up but with data analyzed for all participants on an intention-to-treat basis. The prevalence of pain was lower at 3 postoperative months for pregabalin alone (6% [3 of 50]) and in combination with ketamine (2% [1 of 50]) compared to the control group (34% [17 of 50]; odds ratio = 0.126 [0.022 to 0.5], P = 0.0008; and 0.041 [0.0009 to 0.28], P < 0.0001, respectively) and at 6 months for pregabalin alone (6% [3 of 50]) and in combination with ketamine 0% (0 of 5) compared to the control group (28% [14 of 50]; odds ratio = 0.167 [0.029 to 0.7], P = 0.006; and 0.000 [0 to 0.24], P < 0.0001). Diplopia was more common in both active arms.

CONCLUSIONS

Preoperative administration of 150 mg of pregabalin and postoperative continuation twice daily for 14 days significantly lowered the prevalence of persistent pain after cardiac surgery.

摘要

背景

持续性手术后疼痛很常见,会影响生活质量。本研究假设普瑞巴林和氯胺酮的使用可以预防心脏手术后持续性疼痛。

方法

本随机、双盲、安慰剂对照试验在英国的两个心脏外科中心进行。无慢性疼痛且择期经胸骨切开术行心脏手术的成年人被随机分配至接受常规治疗、普瑞巴林(术前 150mg,术后 14 天每天两次)单药治疗或普瑞巴林联合术后 48 小时静脉输注氯胺酮(0.1mg·kg·h)治疗。主要终点为术后 3 个月和 6 个月时临床显著疼痛的发生率,定义为功能评估 3 次最大咳嗽后的数字评分量表(0-10 分)上的疼痛评分≥4 分。次要结局包括急性疼痛、阿片类药物使用和安全性指标,以及长期神经病理性疼痛、镇痛需求和生活质量。

结果

共纳入 150 例患者,其中 17 例患者退出治疗,2 例患者失访,但所有患者均进行意向治疗分析。与对照组相比,普瑞巴林单药治疗(6%[50 例中的 3 例])和联合氯胺酮治疗(2%[50 例中的 1 例])在术后 3 个月时疼痛发生率较低(34%[50 例中的 17 例];比值比=0.126[0.022 至 0.5],P=0.0008;和 0.041[0.0009 至 0.28],P<0.0001),普瑞巴林单药治疗(6%[50 例中的 3 例])和联合氯胺酮治疗(0%[50 例中的 0 例])在术后 6 个月时疼痛发生率较低(28%[50 例中的 14 例];比值比=0.167[0.029 至 0.7],P=0.006;和 0.000[0 至 0.24],P<0.0001)。两种活性药物组均更常见复视。

结论

术前给予 150mg 普瑞巴林,术后连续 14 天每天两次给药可显著降低心脏手术后持续性疼痛的发生率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验